H2 Rewards Continue: US$25m Cresemba Milestone
H224 continues to be a rewarding period for Basilea Pharmaceutica , with the announcement of a third successive milestone payment for...
top of page
Adam Strydom
Sep 301 min read
Poised for an Eventful H224
Basilea Pharmaceutica ’s H124 results reflect strong momentum across its pipeline and Edison Group expects the pace to accelerate in...
00
Adam Strydom
Sep 301 min read
Another Cresemba Milestone Payment in the Bank
The uptrend in Cresemba sales in Asia-Pacific and China triggered the receipt of Basilea Pharmaceutica ’s third milestone payment of...
00
Adam Strydom
Sep 301 min read
TPOXX Chalks Up Another DoD Contract Win
SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in...
00
Adam Strydom
Jun 251 min read
Final Oncology Asset (Lisavanbulin) Divested
Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the...
00
Adam Strydom
May 311 min read
Can We Make NHI More Affordable?
ALG Newsletter - Can we make NHI more affordable? We look at the signing of the NHI Bill from a slightly different perspective. Can...
00
Adam Strydom
May 211 min read
Cresemba Milestone Payments Continue to Roll in
Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of...
00
Adam Strydom
Apr 181 min read
CARB-X Grant for Preclinical Programs
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a...
10
Adam Strydom
Apr 181 min read
Positive Signals Abound
SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and...
00
Adam Strydom
Apr 181 min read
Zevtera Crosses Key US Regulatory Hurdle
Basilea Pharmaceutica has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe...
00
Adam Strydom
Mar 191 min read
Onwards and Upwards with Strong FY23
SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries...
50
Adam Strydom
Feb 271 min read
From Strength to Strength
FY23 was another strong year for Basilea Pharmaceutica, marked by successive guidance beats and meaningful progress in fortifying its...
30
All
bottom of page